MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma

c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis

(2014) A. Nanbakhsh et al.   BLOOD

Molecular mechanisms of natural killer cell activation in response to cellular stress

(2013) C J Chan et al.   CELL DEATH AND DIFFERENTIATION

Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination

(2013) H Tang et al.   GENE THERAPY

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance

(2012) Lindi Chen et al.   Frontiers in Oncology

Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2

(2011) S. Textor et al.   CANCER RESEARCH

Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

(2011) T. Van Maerken et al.   MOLECULAR CANCER THERAPEUTICS

p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma

(2010) L. Chen et al.   CANCER RESEARCH

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

(2010) J. Carr-Wilkinson et al.   CLINICAL CANCER RESEARCH

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas

(2008) Frank Westermann et al.   GENOME BIOLOGY